Last reviewed · How we verify
NCT06656962: TEST-T-AAGN
The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
Phase 1, PHASE2 trial testing Telitacicept 160mg in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) in 15 participants. Participants enrolled and being followed up; not accepting new ones.
30 December 2025
Quick facts
| Lead sponsor | Renmin Hospital of Wuhan University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 10 October 2024 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Telitacicept 160mg — full drug profile →
- Prednisone (and methylprednisolone) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) — all drugs for Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) →
Sponsor
Renmin Hospital of Wuhan University
Who can join
Adults 18 to 75, any sex, with Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, single-arm, open-label exploratory clinical study conducted in subjects with ANCA-associated nephritis (AAGN), aiming to evaluate the efficacy and safety of Telitacicept in the treatment of AAGN.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evolving Therapeutic Strategies in ANCA-Associated Vasculitis: Current Standards and Emerging Targets for GPA and MPA
Dal Pozzolo R, Iorio L, Davanzo F, Zanatta E, et al · · 2026
Verify or expand the search:
- PubMed search for NCT06656962
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Telitacicept 160mg
Trials testing the same drug.
- NCT07111338 — Telitacicept for PGNMID: A Single-Arm Study · Phase 2 · active not recruiting
- NCT06677801 — Immune Cell Subsets in SLE Patients Treated with Telitacicept · Phase 4 · active not recruiting
- NCT07098897 — To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy · Phase 3 · active not recruiting
- NCT04905212 — A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy · Phase 2 · terminated
Other Renmin Hospital of Wuhan University trials
Trials by the same sponsor.
- NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
- NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
- NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
- NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
- NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06656962 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06656962.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing